Enrollment in TMIST breast cancer screening trial surpasses halfway mark; Black participation rises above 20%

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is more than halfway to its recruiting goal of 128,905 participants, with more than 20% of participants in the United States being Black. Recruitment of women from diverse backgrounds is vital to ensuring that TMIST trial results will be applicable across races, ethnicities, and under-served communities.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Legislation aimed at increasing access to breast and cervical cancer screening was introduced May 22 in the U.S. Senate. The bipartisan Screening for Communities to Receive Early and Equitable Needed Services, or SCREENS, for Cancer Act would reauthorize the National Breast and Cervical Cancer Early Detection Program, or NBCCEDP, for fiscal years 2026 through 2030. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login